Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
It looks to be a good bet that 2009 will mark a second year of growth in new drug approvals as FDA enters the second half of the year with a robust first-half NME approval tally and a well-stocked pipeline of novel agents with user fee goal dates in the remaining months of the year.
You may also be interested in...
Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs
ODAC votes 14-1 against Yondelis in combination with Doxil for ovarian cancer, and 13-0 against Doxil in combination with docetaxel for metastatic breast cancer.
Sticking Point: Novartis Menveo Vaccine Delayed By FDA Request for Info
Novartis has suffered yet another setback over Menveo, its meningococcal meningitis vaccine, thanks to an FDA request for additional information about unspecified clinical and manufacturing issues